Wall Street analysts expect KemPharm, Inc. (NASDAQ:KMPH – Get Rating) to report sales of $3.07 million for the current quarter, Zacks reports. Two analysts provided earnings estimates for KemPharm, with the highest sales estimate of $4.13 million and the lowest estimate of $2.00 million. KemPharm recorded sales of $12.12 million in the same quarter last year, suggesting a negative growth rate of 74.7% year-over-year. The company is expected to release its next quarterly results on Monday, January 1.
According to Zacks, analysts expect KemPharm to report annual revenue of $20.82 million for the current fiscal year, with estimates ranging from $16.22 million to $25.42 million. dollars. For next year, analysts expect the company to post sales of $47.86 million, with estimates ranging from $25.97 million to $69.76 million. Zacks Investment Research’s sales calculations are an average average based on a survey of sell-side analysts who cover KemPharm.
KemPharm (NASDAQ:KMPH – Get Rating) last released its quarterly results on Wednesday, March 30. The specialty pharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, meeting Thomson Reuters consensus estimate of ($0.08). KemPharm recorded a positive return on equity of 7.03% and a negative net margin of 29.86%.
Several analysts have published reports on the company. In a research note on Wednesday, Zacks Investment Research downgraded KemPharm from a “hold” rating to a “sell” rating. StockNews.com supported coverage of KemPharm in a research report on Thursday, March 31. They issued a “holding” rating on the stock. Finally, HC Wainwright upgraded KemPharm from a “neutral” rating to a “buy” rating and raised its price target for the company from $10.00 to $11.00 in a Monday, January 31 research report.
Several large investors have recently increased or reduced their stake in KMPH. Nisa Investment Advisors LLC bought a new position in KemPharm shares in the fourth quarter worth $26,000. Citigroup Inc. increased its position in KemPharm by 139.5% during the third quarter. Citigroup Inc. now owns 3,257 shares of the specialty pharmaceutical company worth $30,000 after purchasing an additional 1,897 shares during the period. Advisor Group Holdings Inc. increased its position in KemPharm by 357.2% during the third quarter. Advisor Group Holdings Inc. now owns 4,535 shares of the specialty pharmaceutical company worth $42,000 after buying 3,543 additional shares during the period. City State Bank bought a new position in KemPharm during the fourth quarter worth $71,000. Finally, Wells Fargo & Company MN increased its position in KemPharm by 72.0% during the second quarter. Wells Fargo & Company MN now owns 5,719 shares of the specialty pharmaceutical company worth $73,000 after purchasing 2,394 additional shares during the period. 34.09% of the shares are held by institutional investors and hedge funds.
KMPH opened at $4.23 on Friday. The company’s 50-day moving average price is $5.23 and its two-hundred-day moving average price is $7.25. KemPharm has a 1 year minimum of $4.10 and a 1 year maximum of $15.70.
KemPharm Company Profile (Get an assessment)
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The Company uses its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.
Get a Free Copy of Zacks Research Report on KemPharm (KMPH)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for KemPharm Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for KemPharm and related companies with MarketBeat.com’s FREE daily newsletter.